MDxHealth Q3 Revenues Increase 145 Percent but Loss Widens

Nov 15, 2012

|

NEW YORK (GenomeWeb News) – MDxHealth said today that revenues in the third quarter rose 145 percent year over year, driven by a 141 percent increase in commercial revenues.

For the three months ended Sept. 30, MDxHealth's total revenues increased to €925,000 ($1.2 million) from €378,000 a year ago, as its commercial revenues climbed to €644,000 from €267,000.

The firm, based in Liege, Belgium, and with offices in Irvine, Calif., did not disclose its expenses for the third quarter. Its net loss for the period increased to €2.3 million from €1.9 million a year ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Featured White Papers

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct

23

Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu